According to the above research reports, combined with our results, we speculated that EA can reduce diabetic neuropathic pain by downregulating Cox and NADH dehydrogenase in the spinal cord, which may mainly be through the following ways: (1) inhibiting the spinal ATP release and P2X7 activation, reducing the spinal neuronal abnormal excitability and microglial activation; (2) reducing spinal ROS production and oxidative phosphorylation injury, inhibiting cell injury and even apoptosis. The gene discussed is P2RX7; the disease is diabetes mellitus.